Cargando…
Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals
SARS-CoV-2 Omicron is the first pandemic variant of concern exhibiting an abrupt accumulation of mutations particularly in the receptor-binding domain that is a critical target of vaccination induced and therapeutic antibodies. Omicron's mutations did only marginally affect the binding of ACE2,...
Autores principales: | Mader, Anna-Lena, Tydykov, Leonid, Glück, Vivian, Bertok, Manuela, Weidlich, Tanja, Gottwald, Christine, Stefl, Alexa, Vogel, Matthias, Plentz, Annelie, Köstler, Josef, Salzberger, Bernd, Wenzel, Jürgen J., Niller, Hans Helmut, Jantsch, Jonathan, Wagner, Ralf, Schmidt, Barbara, Glück, Thomas, Gessner, André, Peterhoff, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920075/ https://www.ncbi.nlm.nih.gov/pubmed/35309727 http://dx.doi.org/10.1016/j.isci.2022.104076 |
Ejemplares similares
-
SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19
por: Glück, Vivian, et al.
Publicado: (2021) -
Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel
por: Glück, Vivian, et al.
Publicado: (2021) -
Humoral immunity in dually vaccinated SARS-CoV-2-naïve individuals and in booster-vaccinated COVID-19-convalescent subjects
por: Glück, Vivian, et al.
Publicado: (2022) -
Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021) -
Casirivimab and imdevimab for COVID-19
Publicado: (2022)